"IPIX STOCK BOTTOM LINE We remain bullish on IPIX
Post# of 72447
(Total Views: 680)
Posted On: 11/09/2020 3:08:43 PM
"IPIX STOCK BOTTOM LINE
We remain bullish on IPIX stock. As we said last month, which can read here, IPIX stock is the cheapest COVID-19 play we have found. Its current market cap is just $83 million compared to $1.5 billion for CytoDyn and $1.1 billion for RLFTF, both of which we have covered here at Insider Financial.
Innovation Pharmaceuticals has been around for so long and its share price depressed that most tend to overlook it, ourselves included. However, we like the data at hand and the potential for the treatment of COVID-19 with Brilacidin and Remdesivir is very compelling. With Gilead, the company behind Remdesivir, sporting a $72 billion market cap, Innovation Pharmaceuticals could be a takeover play as well. The bottom line is that IPIX stock remains a steal at current levels, especially with multiple catalysts coming as the Brilacidin for COVID-19 clinical trial gets underway this quarter."
Full article here:
https://stockdaymedia.com/category/biotech/
We remain bullish on IPIX stock. As we said last month, which can read here, IPIX stock is the cheapest COVID-19 play we have found. Its current market cap is just $83 million compared to $1.5 billion for CytoDyn and $1.1 billion for RLFTF, both of which we have covered here at Insider Financial.
Innovation Pharmaceuticals has been around for so long and its share price depressed that most tend to overlook it, ourselves included. However, we like the data at hand and the potential for the treatment of COVID-19 with Brilacidin and Remdesivir is very compelling. With Gilead, the company behind Remdesivir, sporting a $72 billion market cap, Innovation Pharmaceuticals could be a takeover play as well. The bottom line is that IPIX stock remains a steal at current levels, especially with multiple catalysts coming as the Brilacidin for COVID-19 clinical trial gets underway this quarter."
Full article here:
https://stockdaymedia.com/category/biotech/
(5)
(0)